Did you miss the event? Register for the On-Demand Webinar to learn how digital engagement can solve challenges for both patients and the brand and learn other benefits that will improve patient experience and address multiple barriers to medication adherence.
With more readers and greater engagement in our content than ever, we have many products that can help you reach your customer base through our content, ads, podcasts and online events. Contact us to learn more.
In a landscape where complexity has long been the norm, the power of one lies not just in unification, but in intelligence and automation.
Propeller Health and Novartis received the green light from European regulators to package their products together. The move is one step of many to make digital therapeutics easier to prescribe.
The increased patient-centric focus in drug development by the FDA is highly encouraging and expected to become more mainstream and legislated.
IBM is stopping the development and sales of the product, which uses Watson AI to help pharmaceutical companies find new drugs, because it wasn't yielding large enough financial returns, according to a STAT report.
As pharma continues to close the gap between the operational and analytical needs of their business, they can look to other industries for best practices.
Greenway Health blends smart technology with human expertise to elevate revenue cycle.
The behavioral health epidemic, artificial intelligence and more procedures being done in outpatient settings are some the key 2019 trends that will determine how decision makers purchase technology.
Strategic partnerships are one way for biopharmaceutical companies to expand capabilities and offerings and proactively define their future versus having it defined for them.
A new survey found chief medical information officers believe medication management improvement initiatives have positively impacted patient safety, but factors like workflow variation and a lack of price transparency still compromise patients' well-being.
Panelists highlight Roche's acquisition of Flatiron Health in February and use of AI/ML in drug development.
In a recent interview, Esperion president and CEO, Sheldon Koenig talks about the reality of statin intolerance and his company’s expansion into new diseases
The issue of conflicts of interest has become more pressing in recent years as drug prices soar and healthcare companies reach out to the academic and policy community for advice — often with generous payments attached, ethics experts say.
It's the latest in a series of companies Roche has acquired to add services and technology to the Big Pharma's drug development business, particularly in cancer treatment.
A KHN analysis found that 47 of the drugs cost Medicare and Medicaid almost $12 billion in 2016. The spending totals don’t include rebates, which drugmakers return to the government after paying for the drugs upfront but are not public.
A new report shows a steady growth in so-called "basket studies" in oncology, along with growing interest by the drug industry.
In his plans to cut sky-high drug prices unveiled Friday, Trump said that increasing industry competition will help Americans save at the pharmacy counter.